Hence, patients with mutant KRAS tumors are not eligible for treatment with these drugs; the clinician must have the information on KRAS mutation status of the tumor when assessing the patient; the information provided for clinical decision making must be accurate. This evidence concerns the gene KRAS and neoplasm.